Jazz Pharmaceuticals plc (JAZZ) Financials

JAZZ Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 11.9 billion 7.3 billion
Dec. 31, 2025 11.7 billion 7.3 billion
Sept. 30, 2025 11.4 billion 7.4 billion
June 30, 2025 10.9 billion 7.2 billion

JAZZ Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 388.5 million 74.5 million
Dec. 31, 2025 296.8 million 199.8 million
Sept. 30, 2025 459.4 million 88.1 million
June 30, 2025 100.9 million 64.5 million

JAZZ Net Income

Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 293.1 million
Dec. 31, 2025 -903.6 million
Sept. 30, 2025 251.4 million
June 30, 2025 -718.5 million

JAZZ Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 2.9 billion 4.3 billion 62.2 million
Dec. 31, 2025 2.4 billion 4.3 billion 50.9 million
Sept. 30, 2025 2.0 billion 4.3 billion 53.4 million
June 30, 2025 1.7 billion 4.3 billion 69.0 million

JAZZ Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 66.1 million
Dec. 31, 2025 61.0 million
Sept. 30, 2025 61.6 million
June 30, 2025 61.2 million

JAZZ Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 19.7 million 134.1 million 352.7 million -
Dec. 31, 2025 65.7 million 171.4 million 406.2 million -
Sept. 30, 2025 15.2 million 240.7 million 530.6 million -
June 30, 2025 12.0 million 190.0 million 358.4 million -

JAZZ Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 1.1 billion 306.4 million
Dec. 31, 2025 1.2 billion 24.6 million
Sept. 30, 2025 1.1 billion 257.8 million
June 30, 2025 1.0 billion 116.3 million

JAZZ Revenue by Segment

Graph available only for paid members. Upgrade to see it.

JAZZ

Price: $254.22

52 week price:
105.00
254.22

Payout Ratio Range:
22.18%
119.25%

Earnings Per Share: 0.11 USD

P/E Ratio: 2032.82

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: Ireland

Volume: 468012

Ebitda: 136.8 million

Market Capitalization: 15.3 billion

Links: